Xinmeng Jasmine Mu

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract CT174: Unlocking endocrine resistance: Co-targeting KAT6 and ER with prifetrastat (PF-07248144) and fulvestrant drives tumor and ctDNA response in ER+/HER2− metastatic breast cancer

  Cancer Research · 2026-04-17

• Abstract 4499: KAT6i prifetrastat combines with PI3K pathway inhibitors to drive superior efficacy in preclinical models of PIK3CA mutated ER+ BC.

  Cancer Research · 2026-04-03

• Abstract 6848: HPlot: A novel quantitative framework for spatial profiling of Immune heterogeneity in tumor microenvironments.

  Cancer Research · 2026-04-03

• EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy

  JCI Insight · 2026-01-22

• 18F-FDG PET/CT radiomics for distinguishing LUAD from LUSC in non-small cell lung cancer

  Medicine · 2025-12-05

• Abstract C029: PF-07248144 – First-in-class potent, selective KAT6i in ER+HER2− breast cancer

  Molecular Cancer Therapeutics · 2025-10-22

• Data from Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia

  2025-10-06

• Supplementary Tables S1-14 from Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia

  2025-10-06

• Supplementary Figures S1-8 from Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia

  2025-10-06

• Photoproximity labeling of c-Myc reveals SLK as a cancer specific co-regulatorPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-10-04 · 2 citations

• Two novel 5,5-spiroketal sesquiterpenoid isomers from the roots of <i>Angelica biserrata</i> (R. H. Shan &amp;Yuan) C. Q. Yuan &amp; R. H. Shan

  Natural Product Research · 2025-09-21

• Identification of breast cancer subtypes and drug response prediction through forward and reverse translation

  npj Precision Oncology · 2025-07-31 · 8 citations

• Enhancement of biodegradation of tar-rich coal through sequential treatment by N. mangyaensis and Ochrobactrum sp.

  Scientific Reports · 2025-07-01 · 3 citations

• Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia

  Cancer Discovery · 2025-06-19 · 15 citations

• Abstract LB089: Exploring androgen receptor alterations (ARa) and their potential association with efficacy of first-line (1L) talazoparib (TALA) + enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): A post hoc analysis of TALAPRO-2

  Cancer Research · 2025-04-25

• Abstract CT102: Exploring the tumor molecular landscape associated with<i>TMPRSS2-ERG</i>: A post hoc analysis from the phase 3 TALAPRO-2 study of first-line (1L) talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in metastatic castration-resistant prostate cancer (mCRPC)

  Cancer Research · 2025-04-25

• Abstract 6794: Elucidating mechanisms of cancer cell persistence to lorlatinib in ALK positive NSCLC

  Cancer Research · 2025-04-21

• Abstract 1156: Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors

  Cancer Research · 2025-04-21

• Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors

  Nature Communications · 2025-01-22 · 16 citations

• Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemiaPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2024-12-12 · 5 citations